Trial Profile
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 30 May 2020 This trial is completed in Belgium, Germany and UK (Global End Date: 23 Apr 2020), according to European Clinical Trials Database record.
- 21 May 2020 Status changed from active, no longer recruiting to completed.
- 11 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 May 2021.